Daily Newsletter

22 November 2023

Daily Newsletter

22 November 2023

BeiGene strikes deal worth $1.3bn with Ensem for CDK2 inhibitor 

Ensem will receive an upfront payment and will be eligible for additional payments upon achieving milestones, totalling up to $1.33bn.

Jenna Philpott November 21 2023

BeiGene has acquired an exclusive global licence to an oral cyclin-dependent kinase-2 (CDK2) inhibitor to treat breast cancer from Boston-based Ensem Therapeutics.  

As part of the agreement, Ensem will receive an undisclosed upfront payment and will be eligible for additional payments upon the achievement of defined milestones, in a total of up to $1.33bn, in addition to tiered royalties. According to the company, the new candidate is investigational new drug (IND) application-ready. 

CDK inhibitors block the activity of CDKs, which play a crucial role in breast cancer by promoting abnormal cell cycle progression, contributing to uncontrolled cell growth and tumour formation. 

Most CDK inhibitors target both CDK4 and CDK6. There are three CDK4/6 inhibitors that are US Food and Drug Administration (FDA)-approved to treat certain types of hormone receptor-positive (HR+) HER2-negative breast cancer: Pfizer’s Ibrance (palbociclib), Novartis’ Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).  

Over the years these drugs have been incorporated into the standard of care for this breast cancer subtype, and have become significant revenue drivers for the company. In 2022, Ibrance generated $5.1bn in sales, Kisqali $1.2bn, and Verzenio $1.3bn, as per the companies’ respective 2022 financial reports.  

Still, some breast cancer patients don’t respond to CDK4/6 inhibitors and there are issues of toxicity and building resistance, which limit their effectiveness. Since the initial approvals of these CDK 4/6 inhibitors, the field has branched out to evaluate inhibitors that target other CDK pathways. For example, Pfizer’s tagtociclib is a CDK2 inhibitor currently in Phase II clinical trials for several cancer types, including lung cancer, fallopian tube cancer and triple-negative breast cancer (TNBC). 

Ensem and BeiGene’s CDK2 candidate was developed leveraging Ensem’s Kinetic Ensemble platform, a computational and artificial intelligence (AI)-based drug discovery platform, used to develop small molecule precision medicines for oncology. The Boston-based biotech raised $67m in Series A financing to develop small molecule medicines for difficult-to-drug targets last year.  

In the announcement accompanying the partnership, Ensem CEO Shengfang Jin said: “We believe BeiGene is the right partner to advance our first IND-ready asset due to their wealth of expertise in bringing innovative cancer therapies to patients globally. This partnership validates the capabilities of Ensem’s drug discovery and development team and the ability to rapidly advance potential best-in-class or first-in-class molecules utilising our Kinetic Ensemble platform.” 

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close